Gilead Sciences (Nasdaq:GILD) - Hisse Senedi Fiyatı, Haberler ve Analizler

GILD Stoklara Genel Bakış

GILD temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	1/6
Finansal Sağlık	3/6
Temettüler	4/6

Ödüller

Trading at 59.6% below our estimate of its fair value

Earnings are forecast to grow 35.81% per year

Risk Analizi

Large one-off items impacting financial results

Has a high level of debt

Profit margins (3.8%) are lower than last year (20%)

Dividend of 3.44% is not well covered by earnings

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Navigating Challenges To Shape A Robust Future In Biotech And Healthcare Innovation

Key Takeaways Launch of seladelpar and expansion into HIV treatment with Biktarvy show potential for significant revenue growth through new sales and FDA approvals. Execution of Phase III trials and increased manufacturing capacity signal opportunities for pipeline progression and enhanced contributions to revenue from oncology and liver disease sectors.

View narrative

US$88.42

1.2% overvalued

1.99%

Revenue growth p.a.

5 days ago

Gilead Sciences, Inc. Rakipler

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$90.8b

Amgen

NasdaqGS:AMGN

US$171.6b

AbbVie

NYSE:ABBV

US$359.5b

Biogen

NasdaqGS:BIIB

US$25.3b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Gilead Sciences
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$89.51
52 Haftanın En Yüksek Seviyesi	US$89.74
52 Haftanın En Düşük Seviyesi	US$62.07
Beta	0.20
11 Aylık Değişim	5.82%
3 Aylık Değişim	20.65%
1 Yıllık Değişim	10.32%
33 Yıllık Değişim	35.68%
5 Yıllık Değişim	38.47%
Halka arzdan bu yana değişim	14,044.80%

Son Haberler & Güncellemeler

Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It

Oct 01

Recent updates

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

May 02

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Apr 22

Gilead Sciences: Some Signs Of An Impending Bottom

Apr 22

Gilead Sciences: Realizing Financial Projections Is Key

Mar 20

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Mar 13

Hissedar Getirileri

	GILD	US Biotechs	US Pazar
7D	0.8%	-0.7%	-1.6%
1Y	10.3%	19.8%	30.8%

Getiri vs. Endüstri: GILD underperformed the US Biotechs industry which returned 19.8% over the past year.

Getiri vs Piyasa: GILD underperformed the US Market which returned 30.8% over the past year.

Fiyat Oynaklığı

Is GILD's price volatile compared to industry and market?
GILD volatility
GILD Average Weekly Movement	2.4%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: GILD has not had significant price volatility in the past 3 months compared to the US market.

Zaman İçindeki Volatilite: GILD's weekly volatility (2%) has been stable over the past year.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1987	18,000	Dan O'Day	www.gilead.com

Bir biyofarmasötik şirketi olan Gilead Sciences, Inc. Amerika Birleşik Devletleri, Avrupa ve uluslararası alanda karşılanmamış tıbbi ihtiyaç alanlarında ilaçlar keşfetmekte, geliştirmekte ve ticarileştirmektedir. Şirket, HIV/AIDS tedavisi için Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs ve Atripla ürünlerini; COVID-19 tedavisi için intravenöz kullanım için bir enjeksiyon olan Veklury'yi ve viral hepatit tedavisi için Epclusa, Harvoni, Vemlidy ve Viread'ı sunmaktadır. Ayrıca onkoloji tedavisi için Yescarta, Tecartus ve Trodelvy ürünlerini; pulmoner arteriyel hipertansiyon tedavisi için oral bir formülasyon olan Letairis'i ve ciddi invaziv mantar enfeksiyonlarının tedavisi için lipozomal bir formülasyon olan AmBisome'u sunmaktadır.

Gilead Sciences, Inc. Temel Bilgiler Özeti

Gilead Sciences'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
GILD temel i̇stati̇sti̇kler
Piyasa değeri	US$111.44b
Kazançlar(TTM)	US$1.05b
Gelir(TTM)	US$27.81b

105.7x

F/K Oranı

4.0x

P/S Oranı

GILD aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
GILD gelir tablosu (TTM)
Gelir	US$27.81b
Gelir Maliyeti	US$6.27b
Brüt Kâr	US$21.53b
Diğer Giderler	US$20.48b
Kazançlar	US$1.05b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 06, 2024

Hisse başına kazanç (EPS)	0.85
Brüt Marj	77.44%
Net Kâr Marjı	3.79%
Borç/Özkaynak Oranı	128.3%

GILD uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

3.4%

Mevcut Temettü Verimi

360%

Ödeme Oranı

GILD Stoklara Genel Bakış

Ödüller

Risk Analizi

Navigating Challenges To Shape A Robust Future In Biotech And Healthcare Innovation

Gilead Sciences, Inc. Rakipler

NasdaqGS:REGN

US$90.8b

NasdaqGS:AMGN

US$171.6b

NYSE:ABBV

US$359.5b

NasdaqGS:BIIB

US$25.3b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Chief Medical Officer notifies of intention to sell stock

Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It

Chief Commercial Officer notifies of intention to sell stock

Recent updates

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Chief Medical Officer notifies of intention to sell stock

Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It

Chief Commercial Officer notifies of intention to sell stock

Upcoming dividend of US$0.77 per share

Gilead Sciences: Buy This Bargain Before It's Gone

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Consensus EPS estimates fall by 21%

Second quarter dividend of US$0.77 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?

A Look At Gilead Sciences After Its Recent Weakness

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Records Positive Phase III Results In HIV

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

We Think Some Shareholders May Hesitate To Increase Gilead Sciences, Inc.'s (NASDAQ:GILD) CEO Compensation

Consensus EPS estimates fall by 79%

First quarter dividend of US$0.77 announced

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E Is On The Mark

Gilead Sciences: Some Signs Of An Impending Bottom

Consensus EPS estimates fall by 57%

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences: Realizing Financial Projections Is Key

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Chairman & CEO exercised options and sold US$1.0m worth of stock

Gilead Sciences' (NASDAQ:GILD) Dividend Will Be Increased To $0.77

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Gilead Sciences, Inc. Temel Bilgiler Özeti

105.7x

4.0x

Kazanç ve Gelir

Temettüler

3.4%

360%